From Nasdaq:

Eli Lilly reports promising trial results for a gene therapy that can reverse total hearing loss caused by detrimental mutations in the otoferlin (OTOF) gene, sparking hope and excitement in the industry. This could revolutionize treatments for hearing loss, a historically intractable problem for biopharma businesses. While the financial impact may not be felt until early 2030, there is potential for an addressable market as large as $200 billion. Investors are excited about the company’s innovation and early success, but this shouldn’t be the sole growth driver for the company. Meanwhile, the company continues to see significant growth in sales of obesity and type 2 diabetes treatments.



Read more: Eli Lilly Just Succeeded Where Others Failed, but Does It Matter for the Stock?